原发性胆汁性胆管炎新药开出国内首方，专家解读治疗破局之道

Core Viewpoint - The article discusses the introduction of Seladelpar, the first approved drug for treating Primary Biliary Cholangitis (PBC) in mainland China, highlighting its dual benefits in improving biochemical indicators and alleviating itching symptoms for patients [1][6]. Group 1: Disease Overview - Primary Biliary Cholangitis (PBC) is a rare, chronic autoimmune liver disease that disrupts the immune system, leading to bile duct damage and potential liver complications such as cirrhosis if untreated [3][4]. - The prevalence of PBC in China is reported at 20.5 per 100,000, which, while low compared to other liver diseases, is increasingly recognized due to improved diagnostic capabilities [3][4]. - Symptoms such as itching affect over 70% of PBC patients, significantly impacting their quality of life [3][5]. Group 2: Treatment Landscape - Historically, Ursodeoxycholic Acid (UDCA) has been the primary treatment for PBC, but 30%-40% of patients show inadequate response to this therapy [6][7]. - Seladelpar, a selective PPARδ agonist, represents a new treatment option that can significantly improve biochemical markers and reduce itching, addressing a long-standing challenge in PBC management [6][7][8]. Group 3: Patient Case and Implications - A case study of a patient, referred to as Xiao Liu, illustrates the common struggles faced by PBC patients, including delayed treatment due to a lack of awareness about the disease [7]. - The introduction of Seladelpar is seen as a significant advancement in the treatment of PBC, with clinical studies indicating its effectiveness and safety for Asian patients [8]. Group 4: Regulatory and Market Context - The issuance of the first Seladelpar prescription in China is facilitated by a temporary import policy for urgently needed rare disease medications, reflecting ongoing improvements in the rare disease drug assurance system [8]. - There is an expectation for Seladelpar to undergo formal approval processes in China, with hopes for inclusion in national health insurance to benefit a larger patient population [8].